# United Therapeutics (UTHR) — Analyst Forecast

UTHR · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/uthr/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 13 | 3 | 0 | 16 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $321.00 | $602.00 | $728.00 | 5 |

Last price $541.51 (as of Oct 15, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 8, 2026 | RBC Capital | Maintained | Outperform | $708.00 |
| Oct 7, 2026 | Morgan Stanley | Maintained | Equal-Weight | $566.00 |
| Oct 1, 2026 | BTIG | Upgraded | Neutral → Buy | $728.00 |
| Sep 24, 2026 | Goldman Sachs | Initiated Coverage | Sell | $321.00 |
| Aug 6, 2026 | RBC Capital | Maintained | Outperform | $677.00 |
| Jul 23, 2026 | JP Morgan | Maintained | Overweight | $687.00 |
| Jul 10, 2026 | B of A Securities | Maintained | Neutral | $613.00 |
| Jul 7, 2026 | RBC Capital | Maintained | Outperform | $704.00 |
| May 7, 2026 | Wells Fargo | Upgraded | Equal-Weight → Overweight | $738.00 |
| May 7, 2026 | RBC Capital | Maintained | Outperform | $701.00 |
| Apr 10, 2026 | Morgan Stanley | Maintained | Equal-Weight | $519.00 |
| Mar 31, 2026 | B of A Securities | Maintained | Neutral | $626.00 |
| Mar 31, 2026 | Wells Fargo | Maintained | Equal-Weight | $575.00 |
| Mar 31, 2026 | HC Wainwright & Co. | Maintained | Buy | $660.00 |
| Mar 30, 2026 | TD Cowen | Maintained | Buy | $660.00 |
| Mar 23, 2026 | Wells Fargo | Maintained | Equal-Weight | $486.00 |
| Mar 12, 2026 | Cantor Fitzgerald | Maintained | Overweight | $625.00 |
| Mar 5, 2026 | UBS | Maintained | Buy | $705.00 |
| Feb 26, 2026 | Wells Fargo | Maintained | Equal-Weight | $466.00 |
| Feb 26, 2026 | RBC Capital | Maintained | Outperform | $643.00 |

## Frequently Asked Questions

### What is the price target for UTHR stock?

The average 12-month analyst price target for United Therapeutics (UTHR) is $602.00, with a high estimate of $728.00 and a low of $321.00, across 5 analysts.

### Is UTHR a buy, sell, or hold?

Analysts covering United Therapeutics currently average a Buy rating: 13 buy, 3 hold and 0 sell, from 16 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for UTHR?

The average price target of $602.00 implies 11.17% upside from the last price of $541.51.

### What is the latest analyst rating on UTHR?

On Oct 8, 2026, RBC Capital maintained United Therapeutics at Outperform with a price target of $708.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).